NewAmsterdam Pharma: Positive Obicetrapib Data Leads To New Catalysts
NewAmsterdam Pharma's obicetrapib demonstrates strong phase 3 results. Discover why NAMS stock could rise as further studies ...
BioPharma Dive1d
NewAmsterdam drug shows ‘unexpected’ signs of protecting the heart in latest study
The findings add to evidence that the company’s drug, obicetrapib, could change the narrative surrounding a once-abandoned ...
The Pharma Letter13h
NewAmsterdam leaps on positive trial results
Dutch clinical-stage drug developer NewAmsterdam Pharma saw its shares close up 41% at $26.19 yesterday on positive research ...
Investor's Business Daily on MSN1d
NewAmsterdam Pharma Soars 41% On An Surprise Benefit From Cholesterol Drug
NewAmsterdam Pharma said Tuesday its cholesterol drug lowered the risk of major cardiovascular events and the biotech stock ...
NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
Jefferies, Goldman Sachs & Co., Leerink Partners, TD Cowen, Guggenheim Securities and William Blair are acting as joint book-running managers for the proposed Offering.
Forecasting The Future: 5 Analyst Projections For NewAmsterdam Pharma
During the last three months, 5 analysts shared their evaluations of NewAmsterdam Pharma NAMS, revealing diverse outlooks ...
NewAmsterdam Pharma (NASDAQ:NAMS) Receives Average Recommendation of “Buy” from Analysts
NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) has earned an average recommendation of “Buy” from the six research firms ...
NewAmsterdam Pharma Soars 41% On A Surprise Benefit From Cholesterol Drug
NewAmsterdam Pharma said Tuesday its cholesterol drug lowered the risk of major cardiovascular events and the biotech stock ...
NewAmsterdam Pharma Says Main Goal In Phase 3 BROADWAY Study Achieved; Stock Up In Pre-market
NewAmsterdam Pharma Company N.V. (NAMS), a late-stage, clinical biopharmaceutical company, Tuesday announced positive topline data ...